Advertisement

Topics

FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors

08:44 EDT 24 Aug 2017 | Drug Discovery Development

The FDA is expected to make a decision on approval by February 23, 2018.
Contributed Author: 
Genentech
Topics: 

Original Article: FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement